# EDGAR Filing Document

**Accession Number:** 0001897532
**File Stem:** 0001213900-26-031625
**Filing Date:** 2026-3
**Character Count:** 9849
**Document Hash:** b1737036cf2ecea8c2a964048966124a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-031625.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001213900-26-031625

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260319

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ping An Biomedical Co., Ltd.
- **CENTRAL INDEX KEY:** 0001897532
- **STANDARD INDUSTRIAL CLASSIFICATION:** APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42155
- **FILM NUMBER:** 26772843

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 22/F, CHINA UNITED PLAZA
- **STREET 2:** 1002-1008 TAI NAN WEST STREET
- **CITY:** CHEUNG SHA WAN, KOWLOON
- **NON US STATE TERRITORY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **ZIP:** 0000
- **BUSINESS PHONE:** 852 9710 8044

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 22/F, CHINA UNITED PLAZA
- **STREET 2:** 1002-1008 TAI NAN WEST STREET
- **CITY:** CHEUNG SHA WAN, KOWLOON
- **NON US STATE TERRITORY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **ZIP:** 0000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Majestic Ideal Holdings Ltd
- **DATE OF NAME CHANGE:** 20211206

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2026

Commission File Number No. 001-42155

**Ping An Biomedical Co., Ltd.**

(Registrant's Name)

**22/F, China United Plaza**

**1002-1008, Tai Nan West Street**

**Cheung Sha Wan**

**Kowloon, Hong Kong**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On March 19, 2026, Ping An Biomedical Co., Ltd. (the "**Company**") issued a press release announcing the results of its annual general meeting of shareholders (the "**Meeting**" or "**Annual General Meeting**"), which was held on March 18, 2026, in Hong Kong.

A copy of the press release is furnished as Exhibit 99.1 to this Form 6-K.

**Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 99.1 | [Press Release, dated March 19, 2026, regarding results of the Annual General Meeting](ea028246501ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PING AN BIOMEDICAL CO., LTD.** | **PING AN BIOMEDICAL CO., LTD.** |
| Date: March 19, 2026 | By: | */s/ Pijun Liu* |
|  | Name: | Pijun Liu |
|  | Title: | Chairman of the Board of Directors |

---

## Exhibit 99.1

**Exhibit 99.1**

**All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital**

Hong Kong, March 19, 2026 — Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as "Ping An Bio") announced that shareholders have approved all five resolutions at the company's 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high-vote Class B shares, a targeted share exchange with a major shareholder, and a large-scale share consolidation.

**Authorised Share Capital Changes** 

Shareholders resolved by an ordinary resolution that, the Company authorised share capital of the Company be amended in the manner and sequence set out below with immediate effect (collectively, the **Authorised Share Capital Changes**):

&nbsp;&nbsp;&nbsp;&nbsp;(a) increasing the authorised share capital US$50,000 divided into 800,000,000 ordinary shares of a nominal
or par value of US$0.0000625 each to US$312,500 divided into 5,000,000,000 ordinary shares of a par value US$0.0000625 each, by the addition
of 4,200,000,000 ordinary shares of a par value US$0.0000625 each;

&nbsp;&nbsp;&nbsp;&nbsp;(b) re-designating and re-classifying 4,900,000,000 authorised ordinary shares of a par value US$0.0000625
each (including all existing issued ordinary shares) as 4,900,000,000 class A ordinary shares of par value US$0.0000625 each (the **Class A Shares**), where the rights of the existing ordinary shares shall be the same as the Class A Shares;

&nbsp;&nbsp;&nbsp;&nbsp;(c) cancelling 100,000,000 authorised but unissued ordinary shares of a par value US$0.0000625 each and create
a new share class of 100,000,000 class B ordinary shares of par value US$0.0000625 each (the **Class B Shares**), which will be entitled
to one hundred (100) votes per share,

such that the authorised share capital of the Company shall become US$312,500 divided into 4,900,000,000 class A ordinary shares of a par value US$0.0000625 each and 100,000,000 class B ordinary shares of a par value US$0.0000625 each.

**Adoption of Second Amended and Restated Memorandum and Articles of Association**

Shareholders resolved by a special resolution that the second amended and restated memorandum and articles of association of the Company, in the substantial form attached to the notice of annual general meeting and the proxy statement as Appendix 1 (the **Second Amended MAA**), be adopted in substitution for and to the exclusion of the existing memorandum and articles of association of the Company in its entirety with effect upon the Authorised Share Capital Changes taking effect.

**Share repurchase and issuance** 

Shareholders resolved by an ordinary resolution that, subject to the Authorised Share Capital Changes and Second Amended MAA taking effect and the Company's receipt of the consent to repurchase and application for shares duly executed by INSPIRETECH LTD ("INSPIRETECH"), the Board be and is hereby authorised to repurchase 12,250,000 Class A Shares from INSPIRETECH, all of which are fully paid shares, in consideration of and out of the proceeds of the Company's new issuance of 12,250,000 Class B Shares to INSPIRETECH. The arrangement effectively converts part of INSPIRETECH's holding into high-vote shares while keeping the number of shares held by that shareholder unchanged.

**Share consolidation**

Shareholders resolved by an ordinary resolution that, following the Authorised Share Capital Changes, and conditional upon the approval of the Board, with effect on a date within one (1) calendar year after the conclusion of the Meeting to be determined by the Board:

&nbsp;&nbsp;&nbsp;&nbsp;(d) every one thousand (1,000) then issued and unissued Class A Shares, or such lesser whole share amount
of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class A ordinary share
(the **Consolidated Class A Share(s)**), where such Consolidated Class A Shares shall rank *pari passu* in all respect with each
other and have the same rights and are subject to the same restrictions (save as to par value) as the existing Class A Shares as set out
in the Second Amended MAA;

&nbsp;&nbsp;&nbsp;&nbsp;(e) every one thousand (1,000) then issued and unissued Class B Shares, or such lesser whole share amount
of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class B ordinary share
(the **Consolidated Class B Share(s)**), where such Consolidated Class B Shares shall rank *pari passu* in all respect with each
other and have the same rights and are subject to the same restrictions (save as to par value) as the existing Class B Shares as set out
in the Second Amended MAA;

(collectively, the **Share Consolidation**)

&nbsp;&nbsp;&nbsp;&nbsp;(f) all fractional entitlements to the issued Consolidated Class A Shares and Consolidated Class B Shares
resulting from the Share Consolidation will not be issued to the shareholders of the Company and instead, any fractional shares that would
have resulted from the Share Consolidation will be rounded up to the next whole number; and

&nbsp;&nbsp;&nbsp;&nbsp;(g) the Board be authorised and directed to do all such acts and things as it
may consider necessary or desirable for the purpose of effectuating the Share Consolidation, including determining the definitive ratio
and the effective date of the Share Consolidation and any other changes to the Company's authorised share capital in connection
with and as necessary to effect the Share Consolidation.

**Amendment of Memorandum and Articles of Association reflecting Share Consolidation**

Shareholders resolved by a special resolution that subject to and immediately following the Share Consolidation being effected, the relevant provisions of the memorandum and articles of association of the Company then in effect be amended to reflect the Share Consolidation.

The AGM was held on 18 March 2026, with shareholders of record as of 3 March 2026 entitled to vote in person or by proxy. Each ordinary share carried one vote at the meeting, and all five resolutions received the requisite majority of votes cast, in line with the board of directors' unanimous recommendation.

**About Ping An Biomedical Co., Ltd**

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.

For more information, please contact:

Ping An Biomedical Co., Ltd.

Email: corpsec@pingan365.vip

Celestia Investor Relations

Email: investors@celestiair.com